39 search results for: biologics

expert video

The Potential Impact of Early Intervention in Atopic Dermatitis in Children

2 min

Dermatology

Dr. Amy Paller shares her opinion of whether treatment is needed when children might outgrow their disease.

expert video

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

5 min

Rhinology

Dr. Backer discusses assessing remission in CRSwNP by evaluating the patient's sense of smell in this video clip from the EAACI 2024 symposium.

expert video

When is the right time to consider a biologic in patients with CRSwNP?

5 min

Rhinology

Prof. Hellings and Prof. Corso explain that the right time to implement a biologic depends on academic and reimbursement criteria, which vary by country.

expert video

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

5 min

Rhinology

Prof. Hellings and Prof. Corso highlight that disease severity plays a key role in rate and control of remission in CRS.

expert video

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

5 min

Rhinology

Prof. Hellings and Prof. Corso discuss the significance and rationale behind the new definition of CRSwNP.

expert video

Why Is It Important to Assess Lung Function in Pediatric Severe Asthma Patients?

18 min

Pulmonology

Prof. Monika Gappa presents the importance in assessment of lung function in pediatric patients alongside the associated patient burden.

expert video

The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD

10 min

Dermatology

Dr. Gil Yosipovitch discussed the interaction between type 2 inflammation and itch in AD, the role of type 2 inflammation on neuroarchitecture, and the role of type 2 cytokines in neuronal sensitization.

expert video

Current Treatment Landscape and Emerging Therapies

16 min

Dermatology

Dr. Lawrence F. Eichenfield reviews the evolving therapeutic landscape for children with AD, considering clinically relevant data supporting the use of advanced systemic therapies. This video was recorded at the EADV 2023 annual meeting during the ‘New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management’ presentation.

expert video

The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health

3 min

Dermatology

Dr. Marlies de Graaf highlights the potential long-term consequences of AD in children.

expert video

The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD

3 min

Dermatology

Dr. Stephan Weidinger describes the relationship between skin barrier dysfunction and increased risk of allergen sensitization in AD.

expert video

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

5 min

Dermatology

Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation

interactivity

Prurigo Nodularis: The Patient Journey

5 min

Dermatology

An interactive tool highlighting the disease burden, impact and management of prurigo nodularis throughout the patient journey before diagnosis, during diagnosis and during treatment.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: CanadaChange country/region